Fig. 5

EGCG inhibits SARS-CoV-2 entry. a HEK293T-hACE2 cells were infected with SARS-CoV-2 pseudovirus and treat with EGCG under 4 different conditions as indicated. Cells were lyzed at 48 h postinfection and luciferase activity was measured. Data are shown as mean ± SD of three replicates. b BlaM-containing SARS-CoV-2 S pseudotyped lentivirus was pre-incubated with EGCG for 30 min at 37 °C, subsequently infected HEK293T-hACE2 cells for 4 h to allow virus entry. The cells were then loaded with CCF4-AM to monitor cleavage and shift in fluorescence output for evidence of S mediated viral entry into cells. Percentage of CCF4 cleavage was assessed by flow cytometry on a FACSCanto II. Non-infected cells treated with CCF4-AM were used to set the gate for uncleaved CCF4, which was set to discriminate entry